An antiviral drug originally developed to treat influenza reduces hospitalisation and death from Covid-19 by 50 per cent in patients recently infected with the virus, early trial results suggest. It ...
Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...
After showing a 50% reduction in the risk of hospitalization or death, Merck & Co. and Ridgeback Biotherapeutics’ molnupiravir looks on track to secure an FDA emergency use authorization and become a ...
In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...
This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...
It’s always nice to get some unexpected good news. That’s especially true in COVID World, where the situation (Full hospitals! Thousands of deaths! Protests, stupidity and denial!) always seems ...
Last week, Merck and Ridgeback Biotherapeutics announced Phase 3 results of molnupiravir, an oral antiviral drug, in patients with mild-to-moderate Covid-19. In a trial that included more than 750 ...
An image showing mutations caused by NHC, the active component of molnupiravir to all genes and proteins of another pathogenic coronavirus, MHV. As much as people are justifiably excited about the ...
Submitted by Merck & Co., Inc. KENILWORTH, N.J. & MIAMI, December 28, 2021, /CSRwire/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced ...
Regulators in the U.K. became the first public health body to approve the use of experimental COVID antiviral drug molnupiravir on Thursday. The U.K.'s Medicines and Healthcare Products Regulatory ...
An oral antiviral drug appears to cut the risk of hospitalization and death from COVID-19 by roughly 50 percent in people newly diagnosed with the infection and at risk for severe disease, ...
Pharmaceutical company Merck and Florida-based Ridgeback Biotherapeutics announced Friday that they plan to seek emergency approval for an oral antiviral treatment for COVID-19. If authorized by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback